On March 25, 2021, Diego Miralles, M.D. provided notice that he will resign as a member of the Board of Directors of NeuBase Therapeutics, Inc., effective as of March 31, 2021, in order to focus all his efforts on his new venture. Dr. Miralles served as a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board. Dr. Miralles’s resignation was not the result of any dispute or disagreement with the Company on any matter relating to the operations, policies or practices of the company. On March 26, 2021, the Board appointed Dov A. Goldstein, M.D., a current member of the Board, to the company’s Nominating and Corporate Governance Committee, and appointed Eric Richman, a current member of the Board, as the chairperson of the company’s Nominating and Corporate Governance Committee, each effective as of March 26, 2021.